Literature DB >> 11429543

ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses.

J A Gonzalo1, J Tian, T Delaney, J Corcoran, J B Rottman, J Lora, A Al-garawi, R Kroczek, J C Gutierrez-Ramos, A J Coyle.   

Abstract

We examined the requirement for and cooperation between CD28 and inducible costimulator (ICOS) in effective T helper (TH) cell responses in vivo. We found that both CD28 and ICOS were critical in determining the outcome of an immune response; cytolytic T lymphocyte-associated antigen 4-immunoglobulin (CTLA-4-Ig), ICOS-Ig and/or a neutralizing ICOS monoclonal antibody attenuated T cell expansion, TH2 cytokine production and eosinophilic inflammation. CD28-dependent signaling was essential during priming, whereas ICOS-B7RP-1 regulated TH effector responses, and the up-regulation of chemokine receptors that determine T cell migration. Our data suggests a scenario whereby both molecules regulate the outcome of the immune response but play separate key roles: CD28 primes T cells and ICOS regulates effector responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429543     DOI: 10.1038/89739

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  66 in total

Review 1.  Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma.

Authors:  Christopher A Hunter; Linda A Lieberman; Nicola Mason; Marion Pepper; Sarah L Sague; Cristina Tato; Valerie Zediak
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity.

Authors:  Hiroshi Harada; Alan D Salama; Masayuki Sho; Atsushi Izawa; Sigrid E Sandner; Toshiro Ito; Hisaya Akiba; Hideo Yagita; Arlene H Sharpe; Gordon J Freeman; Mohamed H Sayegh
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 3.  [Mechanisms of specific immunotherapy].

Authors:  I Bellinghausen; J Knop; J Saloga
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

Review 4.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Antigen-independent adhesion and cell spreading by inducible costimulator engagement inhibits T cell migration in a PI-3K-dependent manner.

Authors:  Jennifer L Franko; Alan D Levine
Journal:  J Leukoc Biol       Date:  2008-12-18       Impact factor: 4.962

Review 6.  T-cell costimulatory blockade in organ transplantation.

Authors:  Jonathan S Maltzman; Laurence A Turka
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

7.  Regulation of T cell response by blocking the ICOS signal with the B7RP-1-specific small antibody fragment isolated from human antibody phage library.

Authors:  Masatoshi Maeda; Yuji Ito; Takaaki Hatanaka; Shuhei Hashiguchi; Masaharu Torikai; Toshihiro Nakashima; Kazuhisa Sugimura
Journal:  MAbs       Date:  2009-09-26       Impact factor: 5.857

8.  ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity.

Authors:  Hadi Maazi; Nisheel Patel; Ishwarya Sankaranarayanan; Yuzo Suzuki; Diamanda Rigas; Pejman Soroosh; Gordon J Freeman; Arlene H Sharpe; Omid Akbari
Journal:  Immunity       Date:  2015-03-10       Impact factor: 31.745

9.  ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus.

Authors:  Jared M Odegard; Leah D DiPlacido; Lark Greenwald; Michael Kashgarian; Dwight H Kono; Chen Dong; Richard A Flavell; Joe Craft
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 10.  The role of costimulatory molecules in allergic disease and asthma.

Authors:  Vincent Lombardi; Abinav K Singh; Omid Akbari
Journal:  Int Arch Allergy Immunol       Date:  2009-09-29       Impact factor: 2.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.